AGBETSIVI K. 0. 5. 4. 6. 7.
- Country
- France
- Department
- HEMATOLOGIE
Research Overview
Data & Insights
Has run more than one trial at 0 of 42 partner sites.
Specializations
Multiple Myeloma Management
This investigator specializes in treating newly diagnosed multiple myeloma, with particular focus on therapeutic approaches for patients who are not eligible for transplantation. Their research encompasses innovative combination therapies involving isatuximab, bortezomib, lenalidomide, and dexamethasone.
- First-line Treatment Strategies
- Non-transplant Eligible Patients
- Novel Drug Combinations
Advanced Treatment Approaches
The investigator focuses on developing treatment strategies for relapsed/refractory multiple myeloma. Their work includes evaluating novel therapeutic combinations such as elranatamab monotherapy and various combination regimens including pomalidomide, bortezomib, and carfilzomib.
- Salvage Therapy Protocols
- Treatment-resistant Myeloma
- Novel Agent Evaluation
Post-Transplant Care
Their research extends to post-transplantation maintenance therapy in multiple myeloma patients, investigating the efficacy of various maintenance regimens including elranatamab plus lenalidomide compared to established treatments.
- Maintenance Therapy Optimization
- Long-term Disease Control
- Minimal Residual Disease Monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.